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JOURNAL OF HEPATOLOGYCoffee consumption and reduced self-reported side effects in
HIV-HCV co-infected patients during PEG-IFN and
ribavirin treatment: Results from ANRS CO13 HEPAVIHTo the Editor:
Constentin and colleagues [1] reported key results about the pro-
tective effect of elevated coffee consumption (three or more cups/
day) on histological activity in patients with chronic hepatitis C.
These ﬁndings bring additional evidence to the potential hepato-
protective properties of coffee in chronic liver diseases, as already
suggested in studies showing its beneﬁcial effects on liver cancer
[2].
More recently, Freedman and colleagues [3] showed associa-
tions between elevated coffee consumption (three or more
cups/day) and early, week-20 and sustained virological response
(SVR) during re-treatment with peginterferon alfa-2a (180 lg/
wk) and ribavirin (1000–1200 mg/day) in the HALT trial. The
study also highlighted that the proportion of individuals tolerat-
ing the full dose of treatment was signiﬁcantly higher in those
patients drinking more than three cups of coffee/day. In addition,
during treatment, coffee drinkers were signiﬁcantly less likely to
have a dose reduction due to either low neutrophils or platelets.
These results provide important insights into the double role
that coffee consumption may play in slowing HCV progression,
reducing medical side effects and improving response to HCV
treatment. However, whether and to what extent elevated coffee
consumption may also reduce the burden of patients’ ‘‘personal
experience’’ with HCV disease and/or HCV treatment, as
expressed by self-reported symptoms/side effects, has not yet
been documented.
Individuals receiving HCV treatment experience a considerable
range of symptoms/side effects [4], in particular fatigue, neurocog-
nitive symptoms, depression, and problemsof anger controlwhich
can seriously compromise their quality of life [5] and undermine
adherence and continuity of treatment [6]. On the other hand, sev-
eral performance beneﬁts are attributed to coffee consumption
including physical endurance, fatigue reduction, and improve-
ments in mental concentration and alertness [7].Journal of Hepatology 2Medically reported side effects document major toxicity
events during HCV treatment, whereas self-reported discomfort-
ing symptoms are known to express perceived toxicity and dis-
ease burden on patients’ daily life more accurately.
To test whether elevated coffee consumption can indeed
relieve the discomfort caused by side effects, we used data from
the HEPAVIH ANRS CO13 cohort of HIV-HCV-infected patients
[8]. Selection criteria for this analysis targeted patients receiving
antiretroviral therapy (ART) who started peginterferon alfa-2a
and ribavirin during follow-up and who had both complete data
about coffee consumption before starting treatment and self-
reported discomforting side effects during treatment at 3 months
and before the end of treatment, collected through self-adminis-
tered questionnaires (N = 106, 138 visits). A ﬁve-category vari-
able measured coffee consumption on a ﬁve-point scale: ‘‘no
consumption’’, ‘‘occasional consumption’’, ‘‘one cup per day’’,
‘‘two cups per day’’, ‘‘three or more cups of coffee per day’’.
Self-reported symptoms [9] detailed 30 treatment-related symp-
toms (deﬁned here as ‘‘self-reported side effects’’) over the previ-
ous 4 weeks and the discomfort they caused. This scale has
already been shown to capture HCV-treatment toxicity in HIV-
HCV infected patients [4].
Among the 106 selected patients, median [IQR] age was 44
[41–46] years, men accounted for 71% and most of the partici-
pants (80%) were HIV-infected through injecting drug use (IDU).
At enrollment, 86% of the patients had undetectable plasma HIV
RNA, 52% presented with severe ﬁbrosis (F3–4) and 13% had a
CD4 count <200/mm3. The median [IQR] number of self-reported
side effects causing discomfort was 3 [0–8] and 31% did not
report any discomforting side effects. A mixed model conﬁrmed
that individuals drinking more than three cups a day did not sig-
niﬁcantly change their consumption over time. A logistic regres-
sion model based on Generalized Estimating Equations was used
to study the relationship between coffee consumption before012 vol. 56 j 738–747 745
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starting treatment and the presence of discomforting side effects
at 3 months and before the end of treatment.
Patients drinkingP3 cups of coffee per day were less likely to
report discomforting side effects than non-drinkers of coffee (OR
[95% CI] = 0.19 [0.05–0.78], p = 0.02). The association between
drinking three or more cups and self-reported side effects
remained signiﬁcant (AOR [95% CI]: 0.17 [0.03–0.96], p = 0.04)
even after multiple adjustments for gender, age, history of opioid
use, and liver ﬁbrosis (F3–F4 vs. F0–F1–F2) which are known cor-
relates of reporting a higher number of discomforting side effects
[10]. In addition, the likelihood of reporting discomforting side
effects during HCV treatment linearly decreased across the ﬁve
categories of coffee consumption (OR [95% CI] = 0.67 [0.49–
0.90], p = 0.008) and remained signiﬁcant after multiple adjust-
ment for age, gender, liver ﬁbrosis, and history of opioid use
(AOR [95% CI] = 0.62 [0.43–0.90], p = 0.01).
These results outline an association between elevated coffee
consumption and reduced perceived toxicity during HCV treat-
ment, which needs conﬁrmation in future studies.
Although the study population may be particularly vulnerable
to treatment toxicity and more prone to reporting discomforting
side effects because of their double viral infection, our ﬁndings
suggest the additional potential beneﬁts of coffee consumption
in patients receiving PEG-IFN + ribavirin therapy. While newer
treatment options will soon become available, this combination
will remain the only one available in resource-limited settings
where treatment success is still greatly subordinate to patient
readiness to start, strict adherence, and receipt of adequate side
effects management and counseling. In the meantime,
Constentin’s and Freedman’s results, together with our own,
may provide an inexpensive and simple suggestion to lower necr-
oinﬂammatory injury and potentially reduce the progression of
liver ﬁbrosis, improve response to HCV treatment as well as alle-
viating treatment-related toxicity once patients engage in HCV
treatment.
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